1-20 of 76
Rachel Schiff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract IA21: Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer

Jamunarani Veeraraghavan, Fu-Tien Liao, Lanfang Qin, Tia Gordon, Alekya Raghavan, Caroline Sabotta, Rachel Kaplan, Carolina Gutierrez, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): IA21.
https://doi.org/10.1158/1538-7445.ADVBC23-IA21
Published: 01 February 2024
View article titled, Abstract IA21: Mechanisms of Resistance to HER2-Targeted Therapies in HER2-positive Breast Cancer
Journal Articles

Abstract 386: Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)

Fu-Tien Liao, Lanfang Qin, Martin J. Shea, Igor Bado, Yi-Hsuan Wu, Ling Wu, Yang Gao, Sarmistha Nanda, Tia Gordon, Chia Chia Liu, Xiang H.-F. Zhang, C. Kent Osborne, Mothaffar F. Rimawi, Jamunarani Veeraraghavan, Rachel Schiff
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 386.
https://doi.org/10.1158/1538-7445.AM2023-386
Published: 04 April 2023
View article titled, Abstract 386: Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)
Journal Articles

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Sarmistha Nanda, Martin J. Shea, Rachel Schiff, C. Kent Osborne, Mothaffar Rimawi, Xiaoyong Fu
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P2-03-10.
https://doi.org/10.1158/1538-7445.SABCS22-P2-03-10
Published: 01 March 2023
View article titled, Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer
Journal Articles

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Chia Chia Liu, Lanfang Qin, Shanunak Sathe, Sarmistha Nanda, Jamunarani Veeraraghavan, Ofir Cohen, Nikhil Wagle, Mothaffar Rimawi, C. Kent Osborne, Xiaoyong Fu, Rachel Schiff
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD10-03.
https://doi.org/10.1158/1538-7445.SABCS22-PD10-03
Published: 01 March 2023
View article titled, Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)
Journal Articles

Abstract MS1-1: Oncogene signal transduction and antiestrogen resistance

Rachel Schiff
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): MS1-1.
https://doi.org/10.1158/1538-7445.SABCS22-MS1-1
Published: 01 March 2023
View article titled, Abstract MS1-1: Oncogene signal transduction and antiestrogen resistance
Journal Articles

Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, Lanfang Qin, Xiaoyong Fu, Andrea Gazzo, Antonio Marra, Juan Blanco-Heredia, Britta Weigelt, Jorge Reis-Filho, C. Kent Osborne, Mothaffar Rimawi, Rachel Schiff, Jamunarani Veeraraghavan
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P1-13-17.
https://doi.org/10.1158/1538-7445.SABCS22-P1-13-17
Published: 01 March 2023
View article titled, Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models
Journal Articles

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Agostina Nardone, Xintao Qiu, Sandor Spisak, Zsuzsanna Nagy, Ariel Feiglin, Avery Feit, Gabriela Cohen Feit, Yingtian Xie, Alba Font-Tello, Cristina Guarducci, Francisco Hermida-Prado, Sudeepa Syamala, Klothilda Lim, Miguel Munoz Gomez, Matthew Pun, MacIntosh Cornwell, Weihan Liu, Aysegul Ors, Hisham Mohammed, Paloma Cejas, Jane B. Brock, Matthew L. Freedman, Eric P. Winer, Xiaoyong Fu, Rachel Schiff, Henry W. Long, Otto Metzger Filho, Rinath Jeselsohn
Journal: Cancer Research
Cancer Res (2022) 82 (20): 3673–3686.
https://doi.org/10.1158/0008-5472.CAN-21-3186
Published: 17 October 2022
View article titled, A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Open the PDF for A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications

Jamunarani Veeraraghavan, Fu-Tien Liao, Tia Gordon, Pier Selenica, Sarmistha Nanda, Lanfang Qin, Yingjie Zhu, Juber A. Patel, Andrea Gazzo, Fabio Stossi, Michael A. Mancini, Carolina Gutierrez, Britta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB517A.
https://doi.org/10.1158/1538-7445.AM2022-LB517A
Published: 15 June 2022
View article titled, Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications
Journal Articles

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Chia Chia Liu, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Resel Pereira, Martin J. Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Zhijie Liu, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Xiaoyong Fu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD1-05.
https://doi.org/10.1158/1538-7445.SABCS21-PD1-05
Published: 15 February 2022
View article titled, Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer
Journal Articles

Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer

Jamunarani Veeraraghavan, Sreyashree Bose, Ragini Mistry, Pier Selenica, Sarmistha Nanda, Lanfang Qin, Andrea Gazzo, Yingjie Zhu, Michael A Mancini, Fabio Stossi, Britta Weigelt, Jorge S Reis-Filho, C. Kent Osborne, Mothaffar F Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-06.
https://doi.org/10.1158/1538-7445.SABCS21-PD8-06
Published: 15 February 2022
View article titled, Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer
Journal Articles

Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models

Sreyashree Bose, Ragini Mistry, Chia Chia Liu, Sarmistha Nanda, Lanfang Qin, Pier Selenica, Andrea Gazzo, Yingjie Zhu, Michael A. Mancini, Fabio Stossi, Irmina Diala, Lisa D. Eli, Britta Weigelt, Jorge S. Reis-Filho, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Jamunarani Veeraraghavan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-01.
https://doi.org/10.1158/1538-7445.SABCS21-P4-01-01
Published: 15 February 2022
View article titled, Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of <em>HER</em> and <em>PIK3CA</em> mutations and development of new treatment strategies and study models
Journal Articles

Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Hariprasad Thangavel, Yingmin Zhu, Kurt R. Christensen, Xiaoyong Fu, Dean Edwards, Rachel Schiff, Meghana V. Trivedi
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 930.
https://doi.org/10.1158/1538-7445.AM2021-930
Published: 01 July 2021
View article titled, Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery
Journal Articles

Abstract 1077: Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models

Jamunarani Veeraraghavan, Ragini Mistry, Sarmistha Nanda, Sreyashree Bose, Chia Chia Liu, Vidyalakshmi Sethunath, Martin J. Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Irmina Diala, Alshad S. Lalani, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1077.
https://doi.org/10.1158/1538-7445.AM2021-1077
Published: 01 July 2021
View article titled, Abstract 1077: Acquired neratinib resistance is associated with acquisition of <em>HER2</em> and <em>PIK3CA</em> mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models
Journal Articles

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Vidyalakshmi Sethunath, Xiaoyong Fu, Pamela L Luna, Sarmistha Nanda, Martin Shea, Jamunarani Veeraraghavan, Carmine De Angelis, Huizhong Hu, Chad Shaw, Mothaffar Rimawi, C. Kent Osborne, Rachel Schiff
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS5-29.
https://doi.org/10.1158/1538-7445.SABCS20-PS5-29
Published: 15 February 2021
View article titled, Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)
Journal Articles

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Xiaoyong Fu, Resel Pereira, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Martin Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Mothaffar Rimawi, C Kent Osborne, Rachel Schiff
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD8-03.
https://doi.org/10.1158/1538-7445.SABCS20-PD8-03
Published: 15 February 2021
View article titled, Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer
Journal Articles

Abstract PD3-09: HER2 L755S mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models

Jamunarani Veeraraghavan, Ragini Mistry, Sarmistha Nanda, Vidyalakshmi Sethunath, Martin Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD3-09.
https://doi.org/10.1158/1538-7445.SABCS20-PD3-09
Published: 15 February 2021
View article titled, Abstract PD3-09: <em>HER2 L755S</em> mutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models
Journal Articles

Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models

Jamunarani Veeraraghavan, Ragini Mistry, Sarmistha Nanda, Vidyalakshmi Sethunath, Martin Shea, Tamika Mitchell, Meenakshi Anurag, Michael A. Mancini, Fabio Stossi, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1911.
https://doi.org/10.1158/1538-7445.AM2020-1911
Published: 15 August 2020
View article titled, Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models
Journal Articles

Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Jennifer Torres, Hariprasad Thangavel, Xiaoyong Fu, Rachel Schiff, Meghana V. Trivedi
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3508.
https://doi.org/10.1158/1538-7445.AM2020-3508
Published: 15 August 2020
View article titled, Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer
Journal Articles

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Valerie M. Jansen, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Resel Pereira, Matteo Benelli, Ilenia Migliaccio, Luca Malorni, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Rinath Jeselsohn, Kent Osborne, Rachel Schiff
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS2-01.
https://doi.org/10.1158/1538-7445.SABCS19-GS2-01
Published: 15 February 2020
View article titled, Abstract GS2-01: High levels of interferon-response gene signatures are associated with <em>de novo</em> and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer
Journal Articles

Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Carmine De Angelis, Maria Letizia Cataldo, Agostina Nardone, Jamunarani Veeraraghavan, Xiaoyong Fu, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Resel Pereira, Britta Weigelt, Jorge S. Reis-Filho, Mothaffar F. Rimawi, Rinath Jeselsohn, Kent Osborne, Rachel Schiff
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD2-02.
https://doi.org/10.1158/1538-7445.SABCS19-PD2-02
Published: 15 February 2020
View article titled, Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer